Biomarkers, or markers providing information on the health status of a person, measure cellular, biochemical or molecular changes in human tissues as well as cells or fluids. They contribute to future diagnostics and treatment. The development of biomarkers is time consuming and expensive, requiring the involvement of industry from early stages to better direct the research.
Researchers lack the knowledge of complex commercialization processes and small and medium-sized enterprises (SMEs) have poor understanding of regulatory frameworks.
The BIC platform intended to facilitate knowledge and best practice exchange among business and research representatives, offering tools that support the commercialization process and maturity assessment.
0.00MillionEni + Russia
Valuable tools developed
The BIC project developed the tools to help researchers, SMEs, and technology transfer officers (TTOs) to cope with complex regulations related to the commercialization processes of biomarkers. Additionally, the tools allow the users to better understand clinical and business aspects. They guide researchers and product developers, step by step, through the technology readiness levels (TRL) and remind them of what they need to think about, within each phase of the process. The partners created the “Master Tool” which allows users to access all tools online in one single portfolio and thus simplify the tools´ searchability.
Improved conditions for cooperation
BIC considerably facilitated the collaboration between the research and business sectors as well as simplified the communication with technology transfer officers by standardising the biomarker development processes. The project equipped researchers with knowledge on commercialization while SMEs received assistance to better consider regulatory frameworks. These target groups, which were well involved throughout the project, can now use a common framework and work better together.
The Interreg project BIC used EUR 2.29 million to evaluate biomarkers´ commercialisation processes, simplify its manageability. The project laid grounds for faster and easier biomarker commercialisation that is further upgraded within the project extension phase. This shall speed up the market uptake and improve diagnostics and treatment of citizens across the Baltic Sea region.
01.12.2020A project was set into motion in 2017 with the ambitious aim to facilitate and standardize the commercialization process of new biomarkers. Biomarkers are increasingly important in disease risk prediction, diagnosis, prognosis and treatment response. The BIC project concluded in September 2020 and brought about some tools that can help medical companies to bring new biomarkers to the market faster.Read full story
Ideklinikken, Aalborg University Hospital, The North Denmark Region
- RepresentativeKirstine Rasmussen
University of Copenhagen
- RegionByen København
- RepresentativePer Spindler
Tartu Biotechnology Park OÜ
- RepresentativeMariann Nõlvak
University of Turku
- RepresentativePauli Ollikka
Turku Science Park Ltd
WITHDRAWAL (01/07/2019) ScanBalt
- RegionByen København
- RepresentativePeter Frank
BioCon Valley® GmbH
- RepresentativeThomas Karopka
- RegionVilniaus apskritis
- RepresentativeMonika Kavaliauskė
Wroclaw Technology Park